` MPSYF (MorphoSys AG) vs S&P 500 Comparison - Alpha Spread

MPSYF
vs
S&P 500

Over the past 12 months, MPSYF has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +13% growth.

Stocks Performance
MPSYF vs S&P 500

Loading
MPSYF
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
MPSYF vs S&P 500

Loading
MPSYF
S&P 500
Difference
www.alphaspread.com

Performance By Year
MPSYF vs S&P 500

Loading
MPSYF
S&P 500
Add Stock

Competitors Performance
MorphoSys AG vs Peers

S&P 500
MPSYF
ABBV
AMGN
GILD
VRTX
Add Stock

MorphoSys AG
Glance View

Market Cap
2.8B USD
Industry
Biotechnology

MorphoSys AG emerged from the vibrant biotechnology landscape of Munich, Germany, in 1992. It was founded on the innovative idea of harnessing antibodies as a means to combat diseases. With a precision-driven approach to drug development, MorphoSys primarily concentrates on creating and bringing to market therapeutic agents for cancer and inflammatory disorders. Taking center stage is their proprietary technology platform that enables the discovery of monoclonal antibodies, pivotal in the fight against these daunting ailments. This platform not only serves their internal pipeline but also provides a significant source of revenue through collaborations and licensing agreements with major pharmaceutical giants, enabling MorphoSys to strike timely alliances that bolster both innovation and profitability. Central to MorphoSys's business model is its dual focus: advancing its own pipeline of antibody-based therapeutics while simultaneously offering its technological platforms to partners. This symbiosis allows the company to generate revenue through milestone payments and royalties as partnered drugs advance through clinical trials and into the market. A key asset in its lineup is Monjuvi, a groundbreaking treatment for lymphoma, which underscores the firm's capability to evolve from tech-driven operations to delivering market-ready solutions. As markets grow increasingly competitive, MorphoSys's strategic prowess lies in balancing its R&D investments with collaborative ventures, ensuring a steady revenue stream and a robust presence in the biopharmaceutical realm.

MPSYF Intrinsic Value
24.42 USD
Overvaluation 67%
Intrinsic Value
Price
Back to Top